Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 5/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746608 | 1.00 | QDPR (0.50) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL7149585 | 0.92 | ESR2 (0.55) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL7149586 | 0.92 | ESR2 (0.55) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL10021047 | 0.92 | ACMSD (0.51) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL21237804 | 0.91 | ESR2 (0.56) | QDPRACMSDESR2WDR5ESR1 | |
| SCHEMBL30215678 | 0.90 | ACMSD (0.57) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL21630424 | 0.90 | ACMSD (0.57) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL13072706 | 0.90 | ACMSD (0.57) | QDPRACMSDESR2HDAC4HDAC2 | |
| SCHEMBL21527334 | 0.87 | QDPR (0.71) | QDPRACMSDESR2 | |
| SCHEMBL31063246 | 0.87 | QDPR (0.43) | QDPRACMSDESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-120129678-A | Mitogen-activated protein kinase (MEK) inhibitors | 耐斯泰德医疗公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-110198941-B | Pyrrolopyridine N-oxide derivative and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-110198941-A | Pyrrolopyridine N- oxidized derivatives and its preparation method and application | 江苏豪森药业集团有限公司 | 2019-09-03 | — | — | CN | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014077401-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| CN-1543455-B | 3-phenoxy-4-pyridazinol derivatives and herbicidal compositions containing the same | SANKYO AGRO CO LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-1543455-A | 3-phenoxy-4-pyridazinol derivatives and herbicidal compositions containing the same | 三共农业株式会社 | 2004-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | QDPR 3540/4885ACMSD 4496/4885ESR2 2568/4885 |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | QDPR 801/4885ACMSD 3025/4885ESR2 634/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | QDPR 3785/4885ACMSD 4430/4885ESR2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.